Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 18,288 |
|
|||||
| News | - | ||||||
| Day High | 2.49 | Low High |
|||||
| Day Low | 2.3501 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oncocyte Corporation | OCX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.065 | -2.64% | 2.395 | 12:15:35 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.45 | 2.3501 | 2.49 | 2.46 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 96 | 18,288 | $ 2.40 | $ 43,806 | - | 2.08 - 6.20 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:15:35 | 100 | $ 2.395 | USD |
Oncocyte Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 19.74M | 8.26M | - | 31.98M | -73.42M | -8.89 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncocyte News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.59 | 2.66 | 2.285 | 2.50 | 43,396 | -0.195 | -7.53% |
| 1 Month | 2.94 | 3.30 | 2.285 | 2.71 | 156,560 | -0.545 | -18.54% |
| 3 Months | 3.10 | 3.30 | 2.285 | 2.75 | 57,919 | -0.705 | -22.74% |
| 6 Months | 2.61 | 4.34 | 2.08 | 2.83 | 36,430 | -0.215 | -8.24% |
| 1 Year | 4.80 | 6.20 | 2.08 | 4.10 | 86,560 | -2.41 | -50.10% |
| 3 Years | 93.60 | 125.00 | 2.08 | 38.92 | 344,835 | -91.21 | -97.44% |
| 5 Years | 69.80 | 125.00 | 2.08 | 44.67 | 366,400 | -67.41 | -96.57% |
Oncocyte Description
| OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests. |
